ELIXIRGEN THERAPEUTICS, INC.

BALTIMORE, MD · Founded 2017 · Biotech · Private

Gene therapy and regenerative medicine technologies for rare and aging-associated diseases

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · elixirgentx.com

Sector: Biotech
Headquarters: BALTIMORE, MD
Founded: 2017
Latest Form D: $4M, Nov 2025
Total capital: $33.4M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $33.4M; 8 Form D · last Nov 2025; 11 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 6; 34 pending · first 2020; Rank in peer group#245 of 1449

Capital timeline

Latest events

Nov 2025Private capital raisedForm D · SEC · 8th filing$4M
Apr 2025Private capital raisedForm D · SEC · 7th filing$3.6M
Feb 2025Private capital raisedForm D · SEC · 6th filing$600K
Dec 2023Private capital raisedForm D · SEC · 5th filing$7M
Sep 2022Private capital raisedForm D · SEC · 4th filing$5M
Feb 2021Private capital raisedForm D · SEC · 3rd filing$4.2M
Dec 2019Private capital raisedForm D · SEC · 2nd filing$5M
Jun 2018Private capital raisedForm D · SEC · 1st filing$4M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#245 · top 17%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Akihiro KoExecutive Officer, DirectorNamed in SEC Form D filings
Hiroaki KobayashiDirectorNamed in SEC Form D filings
JEFFREY CLELANDDirectorNamed in SEC Form D filings
Maiko KatadaeDirectorNamed in SEC Form D filings
Minoru KoDirectorNamed in SEC Form D filings
Naonori KurokawaDirectorNamed in SEC Form D filings

Show all 8 people

SHAUNA CALLAHANDirectorNamed in SEC Form D filings
THOMAS WHITEDirectorNamed in SEC Form D filings

What it has protected

USPTO · 6 granted of 40

Jun 11, 2026PendingMethods Of Using ZSCAN4 For Rejuvenating Human CellsUSPTOApplication 19378168
Nov 25, 2025GrantedMethods Of Using ZSCAN4 For Rejuvenating Human CellsUSPTOUS 12,478,659
Nov 25, 2025GrantedMethods Of Using ZSCAN4 For Rejuvenating Human CellsUSPTOUS 12,478,657

Show all 40 patent records

Methods Of Using ZSCAN4 For Rejuvenating Human CellsJun 11, 2026 · Application 19378168Pending
Methods Of Using ZSCAN4 For Rejuvenating Human CellsNov 25, 2025 · US 12,478,659Granted
Methods Of Using ZSCAN4 For Rejuvenating Human CellsNov 25, 2025 · US 12,478,657Granted
Antigens For Cancer ImmunotherapyOct 30, 2025 · Application 19131488Pending
Cell Therapy Protocol Systems And MethodsMay 1, 2025 · Application 18835667Pending
Temperature-based Transient Delivery Of Nucleic Acids And Proteins To Cells And TissuesJan 23, 2025 · Application 18769203Pending
Temperature-controllable, Rna Immunotherapeutic For CancerOct 24, 2024 · Application 18688336Pending
Temperature-controllable, Self-replicating Rna Vaccines For Viral DiseasesAug 15, 2024 · Application 18569589Pending
Temperature-based Transient Delivery Of Nucleic Acids And Proteins To Cells And TissuesAug 13, 2024 · US 12,060,568Granted
Temperature-based Transient Delivery Of ZSCAN4 Nucleic Acids And Proteins To Cells And TissuesFeb 23, 2023 · Application 17789142Pending
Temperature-based Transient Delivery Of Nucleic Acids And Proteins To Cells And TissuesAug 23, 2022 · US 11,421,248Granted
Methods Of Using ZSCAN4 For Rejuvenating Human CellsJul 19, 2022 · US 11,389,504Granted
Methods Of Using ZSCAN4 For Rejuvenating Human CellsAug 18, 2020 · US 10,744,183Granted
Methods Of Using ZSCAN4 For Rejuvenating Human CellsSep 19, 2019 · Application 16427097Pending
Cell Therapy Protocol Systems And MethodsApplication PCTUS2023012300Pending
Antigens For Cancer ImmunotherapyApplication 63427424Pending
Temperature-controllable, Rna Immunotherapeutic For CancerApplication PCTUS2022075789Pending
Temperature-controllable, Rna Immunotherapeutic For CancerApplication 63390216Pending
Temperature-controllable, Rna Immunotherapeutic For CancerApplication 63341318Pending
Cell Therapy SuiteApplication 63306711Pending
Temperature-controllable, Self-replicating Rna Vaccines For Viral DiseasesApplication 63275398Pending
Temperature-controllable, Self-replicating Coronavirus And Influenza Virus Rna VaccinesApplication 63240278Pending
Temperature-controllable, Rna Immunotherapeutic For CancerApplication 63240280Pending
Temperature-controllable, Self-replicating Coronavirus Rna VaccinesApplication 63211974Pending
Temperature-based Transient Delivery Of ZSCAN4 Nucleic Acids And Proteins To Cells And TissuesApplication PCTUS2020067507Pending
Temperature-based Transient Delivery Of Nucleic Acids And Proteins To Cells And TissuesApplication PCTUS2020067506Pending
Temperature-based Transient Delivery Of Nucleic Acids And Proteins To Cells And TissuesApplication 62992700Pending
Temperature-based Transient Delivery Of ZSCAN4 Nucleic Acids And Proteins To Cells And TissuesApplication 62992745Pending
Temperature-based-transient Delivery Of ZSCAN4 Nucleic Acids And Proteins To Cells And TissuesApplication 62955820Pending
Temperature-based-transient Delivery Of Nucleic Acids And Proteins To Cells And TissuesApplication 62955801Pending
Temperature-controllable, Self-replicating Rna Vaccines For Viral DiseasesApplication PCTUS2022034104Pending
Synthetic Mrna Lacking A Polya Tail Or Having A Short Adenine Homopolymer And Methods Of Use And Production ThereofApplication 19153924Pending
Compositions And Methods For Producing Active Proteins From Inactive ProproteinsApplication PCTUS2025025812Pending
Methods For Expression Of Protein From Synthetic Mrna Delivered By InjectionApplication PCTUS2025023042Pending
Methods For Expression Of Protein From Synthetic Mrna Delivered By InjectionApplication 63702025Pending
Methods For Expression Of Protein From Synthetic Mrna Delivered By InjectionApplication 63681682Pending
Compositions And Methods For Producing Active Proteins From Inactive ProproteinsApplication 63637805Pending
Methods For Expression Of Protein From Synthetic Mrna Delivered By Intramuscular InjectionApplication 63575510Pending
Synthetic Mrna Lacking A Polya Tail Or Having A Short Adenine Homopolymer And Methods Of Use And Production ThereofApplication PCTUS2024015869Pending
Antigens For Cancer ImmunotherapyApplication PCTUS2023080800Pending

Growth Curve Bio, LLCSimilar federal contract value in Biotech · null in contracts
PeproMene Bio, Inc.Similar federal contract value in Biotech · null in contracts
Navrogen Inc.Similar federal contract value in Biotech · null in contracts
Fountain Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Appello Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Auron Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.